Karen Batungbacal
On December 31, 2024, the Board appointed Karen Batungbacal as a director of the Company, effective January 20, 2025.
Highest-materiality recent filing
IBEX Limited authorizes $20M share repurchase program over 12 months
Board authorized up to $20M share repurchase starting May 14, 2026, over one year.
IBEX reports record Q3 revenue $164.4M (+17%), raises FY guidance third time
Diluted EPS $0.89 (up 22% YoY); adjusted EPS $0.91 (up 11%).
IBEX reports record Q2 revenue $164.2M (+17% YoY), raises FY revenue & EBITDA guidance
Q2 revenue $164.2M (+16.7% YoY); net income $12.2M; diluted EPS $0.83 (+45% YoY).
Ibex appoints Shuja Keen to board, John Jones as Chair, Mingzhe Zhuang as Lead Independent Director
Shuja Keen reappointed to fill board vacancy; previously served from March 2018 through December 2024.
Ibex shareholder meeting passes all proposals; nominee Khaishgi withdraws
Annual meeting held Dec 5, 2025; all five shareholder proposals approved.
IBEX Limited establishes formal Nominating Committee to address ISS/Glass Lewis concerns
Board formed Nominating Committee on Nov 20, 2025; Chair Daniella Ballou-Aares, members Batungbacal, Beck, McGinnis, Zhuang.
IBEX Q1 revenue $151.2M (+16.5% YoY); EPS $0.82 (+91%), raises FY 2026 guidance
Revenue $151.2M (+16.5% YoY); net income $12.0M (+59.9%); diluted EPS $0.82 vs $0.43.
IBEX reports record Q4 revenue up 18.2%, FY adjusted EPS $2.75, introduces FY2026 guidance
Q4 revenue $147.1M (+18.2% YoY); FY revenue $558.3M (+9.8% YoY), both records.
IBEX reports record Q3 revenue $140.7M (+11% YoY), raises FY guidance, authorizes $15M buyback
Revenue $140.7M, +11% YoY; adjusted EPS $0.82 (+18% YoY), both quarterly records.
IBEX Q2 revenue $140.7M (+6.1% YoY); raises FY guidance; adjusted EPS $0.59
Q2 revenue $140.7M (+6.1% YoY); net income $9.3M (+52.6%); diluted EPS $0.57 vs $0.33 a year ago.
IBEX pays off $25M convertible note from TRGI share repurchase using HSBC credit lines
On Jan 9, 2025, IBEX paid in full the $25M convertible promissory note issued to TRGI on Nov 19, 2024.
IBEX appoints Karen Batungbacal to board; Shuja Keen retires
Karen Batungbacal appointed independent director, effective Jan 20, 2025; brings CX expertise from JPMorgan Chase, UnitedHealth Group.
IBEX Limited shareholders elect directors, approve auditor at 2024 annual meeting
Shareholders approved setting maximum number of directors at eight with 14,255,011 votes for and 20,629 against.
Repurchased 3,562,341 shares at $19.65 each from TRGI, representing ~20% of diluted shares outstanding.
IBEX reports record Q1 FY25 revenue $129.7M, adj. EBITDA margin 12.0%, raises FY guidance
Revenue $129.7M (+4.1% YoY); diluted EPS $0.43 (+9.6% YoY).
Ibex Limited enters $75M credit facilities with HSBC, replacing $80M PNC facility
$25M US secured revolving facility with HSBC Bank USA; SOFR+2% or ABR+1%.
IBEX appoints McGinnis and Zhuang to board; Leone and Kleisterlee exit
John Leone resigned effective Oct 24; Gerard Kleisterlee to retire after Dec 5 AGM.
IBEX Q4 rev $124.5M, net income up 118% YoY; FY2024 record EPS $1.84; guides FY2025 rev $510-525M
Q4 revenue $124.5M (flat YoY); net income $9.8M (+118%); diluted EPS $0.56 (+133%).
Revenue $126.8 million (-3.6% YoY); net income $10.3M ($0.57 diluted EPS) vs $11.3M ($0.59) prior year.
On December 31, 2024, the Board appointed Karen Batungbacal as a director of the Company, effective January 20, 2025.
On December 31, 2024, the Board determined it to be in the best interests of the Company to appoint each of the Continuing Directors, effective December 31, 2024, to fill the resulting vacancies until the next annual general meeting or until their successors are elected or appointed or their office is otherwise vacated.
On December 31, 2024, the Board determined it to be in the best interests of the Company to appoint each of the Continuing Directors, effective December 31, 2024, to fill the resulting vacancies until the next annual general meeting or until their successors are elected or appointed or their office is otherwise vacated.
On December 31, 2024, Shuja Keen informed IBEX Limited (the “Company”) that, pursuant to the terms and conditions of a purchase agreement, dated as of November 19, 2024 (the “Agreement”), between the Company and The Resource Group International Limited (“TRGI”), he intended to resign from the Company’s Board of Directors (the “Board”), including the Compensation Committee and Nominating and Governance Committee thereof, effective immediately.
On December 31, 2024, the Board determined it to be in the best interests of the Company to appoint each of the Continuing Directors, effective December 31, 2024, to fill the resulting vacancies until the next annual general meeting or until their successors are elected or appointed or their office is otherwise vacated.
On December 31, 2024, the Board determined it to be in the best interests of the Company to appoint each of the Continuing Directors, effective December 31, 2024, to fill the resulting vacancies until the next annual general meeting or until their successors are elected or appointed or their office is otherwise vacated.
On December 31, 2024, the Board determined it to be in the best interests of the Company to appoint each of the Continuing Directors, effective December 31, 2024, to fill the resulting vacancies until the next annual general meeting or until their successors are elected or appointed or their office is otherwise vacated.
On October 24, 2024, Mr. Gerard Kleisterlee notified the Board of his intent to retire from the Board effective as of the Company’s 2024 Annual General Meeting of Shareholders.
On October 24, 2024, the Company received notice from TRGI of its appointment of Mr. Patrick McGinnis to the Board, effective as of October 24, 2024,
On October 24, 2024, Mr. John Leone notified the Board of Directors (the “Board”) of IBEX Limited (the “Company”) of his intent to resign from the Board effective as of October 24, 2024.
the Board appointed Ms. Fiona Beck to fill Mr. Leone’s vacancy on October 24, 2024 and to serve on the Audit Committee.
and the appointment of Mr. Mingzhe (JJ) Zhuang (together with Mr. McGinnis, the “Appointed Directors”) to the Board, effective as of the 2024 Annual Meeting of Shareholders.
Max materiality 0.85 · Median 0.65 · Most common event earnings